Published in Stat Med on December 15, 2003
Sample size determinations in original research protocols for randomised clinical trials submitted to UK research ethics committees: review. BMJ (2013) 1.15
The effect of inhaled IFN-β on worsening of asthma symptoms caused by viral infections. A randomized trial. Am J Respir Crit Care Med (2014) 1.11
GLUMIP 2.0: SAS/IML Software for Planning Internal Pilots. J Stat Softw (2008) 0.90
Unplanned adaptations before breaking the blind. Stat Med (2012) 0.86
A review and re-interpretation of a group-sequential approach to sample size re-estimation in two-stage trials. Pharm Stat (2014) 0.82
Practical Methods for Bounding Type I Error Rate with an Internal Pilot Design. Commun Stat Theory Methods (2007) 0.82
Connections between permutation and t-tests: relevance to adaptive methods. Stat Med (2014) 0.78
OARSI Clinical Trials Recommendations: Key analytic considerations in design, analysis, and reporting of randomized controlled trials in osteoarthritis. Osteoarthritis Cartilage (2015) 0.78
Maximum type I error rate inflation from sample size reassessment when investigators are blind to treatment labels. Stat Med (2015) 0.75
Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy. Kidney Int (2011) 2.34
Automated electronic reminders to facilitate primary cardiovascular disease prevention: randomised controlled trial. Br J Gen Pract (2010) 2.32
Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology (2005) 2.00
Planning and analysis of three-arm non-inferiority trials with binary endpoints. Stat Med (2007) 1.54
Warwick-Edinburgh Mental Well-being Scale (WEMWBS): validated for teenage school students in England and Scotland. A mixed methods assessment. BMC Public Health (2011) 1.45
Robustness of methods for blinded sample size re-estimation with overdispersed count data. Stat Med (2013) 1.39
Telephone peer-delivered intervention for diabetes motivation and support: the telecare exploratory RCT. Patient Educ Couns (2008) 1.32
Nonmotor and diagnostic findings in subjects with de novo Parkinson disease of the DeNoPa cohort. Neurology (2013) 1.26
Pro-active call center treatment support (PACCTS) to improve glucose control in type 2 diabetes: a randomized controlled trial. Diabetes Care (2005) 1.20
A group-sequential design for clinical trials with treatment selection. Stat Med (2008) 1.20
A comparison of peritonitis in polycystic and non-polycystic patients on peritoneal dialysis. Perit Dial Int (2004) 1.03
Cross cultural evaluation of the Warwick-Edinburgh Mental Well-being Scale (WEMWBS) --a mixed methods study. Health Qual Life Outcomes (2013) 0.98
Sources of information and behavioral patterns in online health forums: observational study. J Med Internet Res (2014) 0.97
Anticholinergics for urinary symptoms in multiple sclerosis. Cochrane Database Syst Rev (2009) 0.96
Safety and Efficacy of the ACE-Inhibitor Ramipril in Alport Syndrome: The Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase III EARLY PRO-TECT Alport Trial in Pediatric Patients. ISRN Pediatr (2012) 0.96
Adaptive designs for confirmatory clinical trials with subgroup selection. J Biopharm Stat (2014) 0.91
Bladder symptoms in multiple sclerosis: a review of pathophysiology and management. Expert Opin Drug Saf (2010) 0.91
A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis. Mult Scler (2010) 0.90
A comparison of methods for treatment selection in seamless phase II/III clinical trials incorporating information on short-term endpoints. J Biopharm Stat (2015) 0.88
Time-patterns of annualized relapse rates in randomized placebo-controlled clinical trials in relapsing multiple sclerosis: a systematic review and meta-analysis. Mult Scler (2012) 0.88
Adhesion maturation of neutrophils on nanoscopically presented platelet glycoprotein Ibα. ACS Nano (2013) 0.87
Trends in annualized relapse rates in relapsing-remitting multiple sclerosis and consequences for clinical trial design. Mult Scler (2011) 0.87
Systematic review of randomized controlled trials of clinical prediction rules for physical therapy in low back pain. Spine (Phila Pa 1976) (2013) 0.86
Practice nursed-based, individual and video-assisted patient education in oral anticoagulation--protocol of a cluster-randomized controlled trial. BMC Fam Pract (2011) 0.86
Blinded sample size re-estimation in crossover bioequivalence trials. Pharm Stat (2014) 0.84
Assessment of statistical significance and clinical relevance. Stat Med (2012) 0.83
Educating orally anticoagulated patients in drug safety: a cluster-randomized study in general practice. Dtsch Arztebl Int (2014) 0.83
Reporting FDR analogous confidence intervals for the log fold change of differentially expressed genes. BMC Bioinformatics (2011) 0.83
Explaining temporal trends in annualised relapse rates in placebo groups of randomised controlled trials in relapsing multiple sclerosis: systematic review and meta-regression. Mult Scler (2013) 0.83
Efficacy of Ambroxol lozenges for pharyngitis: a meta-analysis. BMC Fam Pract (2014) 0.82
Development of oral immunomodulatory agents in the management of multiple sclerosis. Drug Des Devel Ther (2011) 0.81
Biometrical journal and reproducible research. Biom J (2009) 0.80
Study protocol: improving patient choice in treating low back pain (IMPACT-LBP): a randomised controlled trial of a decision support package for use in physical therapy. BMC Musculoskelet Disord (2011) 0.80
Validation and reliability of the Neuropathic Pain Scale (NPS) in multiple sclerosis. Clin J Pain (2007) 0.80
Data-driven treatment selection for seamless phase II/III trials incorporating early-outcome data. Pharm Stat (2014) 0.80
Safety relevant knowledge of orally anticoagulated patients without self-monitoring: a baseline survey in primary care. BMC Fam Pract (2014) 0.80
Primum non nocere: shared informed decision making in low back pain--a pilot cluster randomised trial. BMC Musculoskelet Disord (2014) 0.79
Scientific Versus Experiential Evidence: Discourse Analysis of the Chronic Cerebrospinal Venous Insufficiency Debate in a Multiple Sclerosis Forum. J Med Internet Res (2015) 0.79
Interleukin-2 receptor antagonists for pediatric liver transplant recipients: a systematic review and meta-analysis of controlled studies. Pediatr Transplant (2014) 0.79
Perspectives on the use of adaptive designs in clinical trials. Part II. Panel discussion. J Biopharm Stat (2010) 0.79
Blinded assessment of treatment effects utilizing information about the randomization block length. Stat Med (2009) 0.78
Design and semiparametric analysis of non-inferiority trials with active and placebo control for censored time-to-event data. Stat Med (2013) 0.78
Optimal choice of the number of treatments to be included in a clinical trial. Stat Med (2009) 0.77
Considerations on what constitutes a 'qualified statistician' in regulatory guidelines. Stat Med (2011) 0.77
Therapeutic apheresis in pediatric patients with acute CNS inflammatory demyelinating disease. Blood Purif (2013) 0.77
Design and development of a decision support package for low back pain. Arthritis Care Res (Hoboken) (2014) 0.76
Spline-based procedures for dose-finding studies with active control. Stat Med (2014) 0.75
WITHDRAWN: Anticholinergics for urinary symptoms in multiple sclerosis. Cochrane Database Syst Rev (2015) 0.75
Power and sample size determination when assessing the clinical relevance of trial results by 'responder analyses'. Stat Med (2004) 0.75
Blinded and unblinded internal pilot study designs for clinical trials with count data. Biom J (2013) 0.75
Effect of the left internal mammary artery to the left anterior descending artery on mortality and morbidity after combined coronary and valve operations. Ann Thorac Surg (2005) 0.75
An Unconditional Test for Change Point Detection in Binary Sequences with Applications to Clinical Registries. Methods Inf Med (2016) 0.75